Another study detected that silencing expression of IGFBP-6 or IGF-I or IGF-II through applying siRNA mechanism as well as knockdown IGF-1R activity on fibroblasts could lead to altering fibroblast mobilization, attenuating tumor invasion and TME remodeling through the IGFs/IGF-1R axis in breast epithelial cells which can be considered as a helpful tool for pivotal therapeutic of breast cancer related to dysregulation of IGF signaling pathway (De Vincenzo et al., 2019). The gene discussed is IGF2; the disease is neoplasm.